Antigenotoxic effects of resveratrol: assessment of in vitro and in vivo response

被引:20
作者
Abraham, Suresh K. [1 ]
Khandelwal, Nidhi [1 ]
Hintzsche, Henning [2 ]
Stopper, Helga [2 ]
机构
[1] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India
[2] Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany
关键词
DOSE-RESPONSE; CANCER; CHEMOPREVENTION; GENOTOXICITY; DAMAGE; DNA; PHYTOCHEMICALS; ANTIOXIDANTS; MUTAGENICITY; MICRONUCLEI;
D O I
10.1093/mutage/gev048
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Experiments were performed to evaluate the in vitro and in vivo dose response for antigenotoxic effects of resveratrol (RES). For the in vitro study, HL-60 cells were co-treated with the test genotoxin and three concentrations of RES. Thereafter, genotoxic effects were assessed in the cytokinesis-block micronucleus test. Results of the in vitro experiments using genotoxins nitroquinoline-1-oxide (NQO) and mitomycin C (MMC) showed maximum inhibition of genotoxicity with the lowest test concentration of RES. The mouse bone marrow micronucleus assay was used for evaluating the in vivo antigenotoxic effects of RES against genotoxins diepoxybutane (DEB), MMC, methyl methanesulfonate and procarbazine (PCB). The experimental animals received RES pre-treatment by gavage 30 min, 24 and 48 h before injecting the genotoxin intraperitoneally. The in vivo studies demonstrated efficacy of the lowest test dose of RES for exerting maximum protection against chromosomal damage induced by all four genotoxins. The antigenotoxic effect observed with 6.25 mg/kg RES was significantly higher than that of 100 mg/kg RES against PCB and DEB. In conclusion, the findings from the present study indicate that lower test concentrations/doses of RES are more effective in exerting antigenotoxic effects.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 41 条
[1]   Anti-genotoxicity of trans-anethole and eugenol in mice [J].
Abraham, SK .
FOOD AND CHEMICAL TOXICOLOGY, 2001, 39 (05) :493-498
[2]   Analysis of in vitro chemoprevention of genotoxic damage by phytochemicals, as single agents or as combinations [J].
Abraham, Suresh K. ;
Eckhardt, Alexander ;
Oli, Rajaraman G. ;
Stopper, Helga .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2012, 744 (02) :117-124
[3]   In vitro and in vivo mutagenicity of the butadiene metabolites butadiene diolepoxide, butadiene monoepoxide and diepoxybutane [J].
Adler, ID ;
Kliesch, U ;
Nylund, L ;
Peltonen, K .
MUTAGENESIS, 1997, 12 (05) :339-345
[4]   Influence of resveratrol on oxidative damage in genomic DNA and apoptosis induced by cisplatin [J].
Attia, Sabry M. .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2012, 741 (1-2) :22-31
[5]   Effects of resveratrol on topoisomerase II-α activity: induction of micronuclei and inhibition of chromosome segregation in CHO-K1 cells [J].
Basso, Emiliano ;
Fiore, Mario ;
Leone, Stefano ;
Degrassi, Francesca ;
Cozzi, Renata .
MUTAGENESIS, 2013, 28 (03) :243-248
[6]   Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[7]   Effect of resveratrol on chromosomal aberrations induced by doxorubicin in rat bone marrow cells [J].
Bingol, Gunsel ;
Gulkac, Mehmet Dogan ;
Dilhoglugil, Meltem Ozlen ;
Polat, Fikriye ;
Kanli, Aylin Ozon .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2014, 766 :1-4
[8]   Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter? [J].
Borriello, Adriana ;
Bencivenga, Debora ;
Caldarelli, Ilaria ;
Tramontano, Annunziata ;
Borgia, Alessia ;
Pirozzi, Anna Virginia Adriana ;
Oliva, Adriana ;
Della Ragione, Fulvio .
CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (30) :5384-5393
[9]   Phytoalexin resveratrol attenuates the mutagenicity of the heterocyclic amines 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline [J].
Boyce, A ;
Doehmer, J ;
Gooderham, NJ .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 802 (01) :217-223
[10]  
Bradamante S, 2004, CARDIOVASC DRUG REV, V22, P169